{"id":"NCT01360554","sponsor":"Pfizer","briefTitle":"ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","officialTitle":"Archer 1009:a Randomized, Double Blind Phase 3 Efficacy And Safety Study Of Pf-00299804 (Dacomitinib) Versus Erlotinib For The Treatment Of Advanced Non-small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06-16","primaryCompletion":"2013-09-30","completion":"2015-09-14","firstPosted":"2011-05-25","resultsPosted":"2017-05-24","lastUpdate":"2017-05-24"},"enrollment":878,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Dacomitinib (PF-00299804)","otherNames":[]},{"type":"DRUG","name":"Active Comparator (erlotinib)","otherNames":[]},{"type":"DRUG","name":"Placebo erlotinib","otherNames":[]},{"type":"DRUG","name":"Placebo PF00299804","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer, previously treated with at least one prior regimen. Analyses of primary objective (Progression Free Survival) will be done in two co-primary populations as defined in the protocol.","primaryOutcome":{"measure":"Progression-Free Survival (PFS) Per Independent Radiologic Review.","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.","effectByArm":[{"arm":"Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo)","deltaMin":2.6,"sd":null},{"arm":"Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo)","deltaMin":2.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.195"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":224,"countries":["United States","Austria","Belgium","China","Denmark","Finland","France","Germany","Greece","Hungary","India","Ireland","Japan","Mexico","Poland","Russia","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["26768165","25439691"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7471009&StudyName=ARCHER%201009%20%3A%20A%20Study%20Of%20Dacomitinib%20%28PF-00299804%29%20Vs.%20Erlotinib%20In%20The%20Treatment%20Of%20Advanced%20Non-Small%20Cell%20Lung%20Cancer%20%0A"]},"adverseEventsSummary":{"seriousAny":{"events":178,"n":436},"commonTop":["Diarrhoea","Rash","Decreased appetite","Nausea","Fatigue"]}}